arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Dianthus Therapeutics, Inc. /DE/

DNTH
$83.16 ▼ -2.64 (-3.08%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
40 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Dianthus Therapeutics, Inc. /DE/ faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7B
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -4.1% ↘
FCF / Share $-0.87 ↘
Trailing P/E —
Price / Book 3.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$284.00K
↓ -78.6% —
Net Income Profit after all expenses
$-40.83M
↓ -38.4% —
FCF / Share Free cash flow per share
$-0.87
↓ -45.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
22
Cash Quality ↓
53

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 40 quarters